# OnCo record paper-prodige-24-five-year-outcomes-jama-oncol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-prodige-24-five-year-outcomes-jama-oncol-2022" ;
  schema:name "Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial"@en ;
  schema:description "The 2022 five-year report of PRODIGE 24 confirming that modified FOLFIRINOX after pancreatic cancer surgery gives a median survival of about four and a half years against three with gemcitabine, and that 43 percent of patients were alive at five years."@en ;
  schema:url <https://onco.cc/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2022.3829>, <https://pubmed.ncbi.nlm.nih.gov/36048453/>, <https://clinicaltrials.gov/study/NCT01526135> ;
  onco:tag "pancreatic-evidence" ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2022.3829> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Conroy T, Castan F, Lopez A, et al." ;
  onco:related <https://onco.cc/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/>, <https://onco.cc/key-papers/paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/unicancer/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/hazard-ratio/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct05968326/> ;
  onco:people <https://onco.cc/people/thierry-conroy/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .